But is this an overreaction to the NeuroVax Phase I/II results? Immune Response (IMNR) rose over 50% today, but later settled back to about 2.17 at the time of this writing, about 33% over it’s close yesterday. Prompting the rise was its announcement yesterday at the 54th annual meeting of the American Academy of Neurology (AAN) held in San Francisco , that its T-cell receptor (TCR) peptide vaccine, NeuroVax, produced an immune response in 94 percent of the patients with multiple sclerosis. While this is great news for Immune Response, our concern is that the market is getting a bit overheated and ignoring the fact that the Phase III hurdle is a huge one. And, as is the case with Phase I/II trials, the sample was small... there where only 37 patients total, and only 16 received the NeuroVax combination of TCR peptides from three families (BV5S2, BV6S5, and BV13S1) plus an adjuvant.
